#AHA25
Get this: Coffee suppressed atrial fibrillation!
Unexpected results for recurrence from a randomized trial in participants after cardioversion from AF
#AHA25 @jama.com
jamanetwork.com/journals/jam...
November 9, 2025 at 2:51 PM
Giving a lecture tomorrow at #AHA25 in New Orleans. Making sure some of my other senses are well taken care of tonight!
November 9, 2025 at 5:55 AM
Excellent presentation by Professor Erin Michos @erinmichos.bsky.social at #AHA25
November 8, 2025 at 4:40 PM
A randomized clinical trial published in JAMA found that patients with AF who consumed caffeinated coffee had a lower risk of recurrent AF or atrial flutter compared with those who abstained.

#AHA25 #AFib @ahascience.bsky.social

ja.ma/47vUbDB
November 9, 2025 at 5:00 PM
First time in NOLA, attending #AHA25 to talk about the utility of #zebrafish for discovering mechanisms in heart #devbio and disease! ❤️🫀🐟🧬
November 7, 2025 at 12:51 AM
ANGPTL3, presented at #AHA25 showed gene editing demonstrates few adverse events.

More from Dr. Harrington👇👇
November 9, 2025 at 4:24 PM
Let's do this - cardiac #devbio #AHA25:
November 7, 2025 at 3:35 PM
In a meta-analysis of 17,801 patients with myocardial infarction and preserved LVEF (≥50%), beta-blockers did not reduce death, MI, or heart failure over a median 3.6 years of follow-up. Full results: nej.md/43U5Ppo

#AHA25
November 9, 2025 at 4:14 PM
#ESCTVOntheRoad 🚍 at #AHA25

Eugenia Gianos shares groundbreaking insights from the primary findings of the VESALIUS-CV Trial.
November 8, 2025 at 8:36 PM
🧵 #AHA25 attendees, check out these key findings from today's JAMA and @jamacardiology.com presentations:

Among people with PAD and no #diabetes, metformin treatment for 6 months did not result in improvements in walking ability or secondary outcomes vs placebo. ja.ma/4oqMJzr
November 9, 2025 at 2:25 AM
If you’re at #AHA25, don’t miss this session on Saturday afternoon!

❤️‍🩹 Impact of Caregiver Burden on Cardiovascular and Brain Health
⏰ 3:15 - 4:30 PM (CST)
📍 240 - 241
AHA25
eppro02.ativ.me
November 8, 2025 at 1:44 AM
📊 Research Summary: Adults with #AFib who drank at least one cup of caffeinated coffee daily after successful cardioversion had a lower risk of recurrence than those who abstained from coffee and caffeine.

#AHA25 @ahascience.bsky.social

ja.ma/4nLL5r0
November 9, 2025 at 3:15 PM
📖 Read all the @jama.com and @jamacardiology.com papers presented today at #AHA25.

➡️ ja.ma/3JD1YX2
November 9, 2025 at 2:25 AM
Get insights from Ulf Landmesser on the CLOSURE-AF Trial

#ESCTVOntheRoad 🚍 at #AHA25
November 8, 2025 at 10:01 PM
Calling all coffee drinkers! Dr. Khan has good news from the DECAF trial presented at #AHA25. ☕☕☕
November 9, 2025 at 4:21 PM
In patients with atrial fibrillation after successful ablation, rivaroxaban therapy did not lead to a significantly lower incidence of a composite of stroke, systemic embolism, or new covert embolic stroke than aspirin therapy. Full OCEAN trial results: nej.md/3LsRJ86

#AHA25
November 8, 2025 at 8:20 PM
⚜️ And, that’s day 1 of #AHA25! ⚜️

📰 Our team’s coverage will continue tomorrow!

🫀 In the meantime, catch up with our reports on some of the big late-breaking sessions here ⬇️

www.healio.com/news/cardiol...

@gohealio.bsky.social @americanheart.bsky.social
November 9, 2025 at 1:05 AM
RCT: Patients with #AFib who continued their usual caffeinated coffee intake after cardioversion experienced less recurrence of AF or atrial flutter compared to those who abstained from coffee and caffeine.

#AHA25 @ahascience.bsky.social

ja.ma/47FZkaR
November 9, 2025 at 3:00 PM
DR10624 results presented at #AHA25
November 8, 2025 at 6:02 PM
🎥 Hear from Roxana Mehran as she breaks down the key findings and clinical implications of the DECAF Trial – straight from #AHA25

#ESCTVOntheRoad
November 9, 2025 at 3:53 PM
📢 POLY-HF: Daily Polypill Boosts Heart Function, QOL, and Cuts Hospitalizations in Underserved Patients With #HFrEF

Read more: https://bit.ly/4hV9byv

#AHA25 #HeartFailure #CardioSky #MedSky
November 10, 2025 at 10:35 PM
Among patients with atherosclerosis or diabetes but no previous myocardial infarction or stroke, evolocumab led to a lower risk of major adverse cardiovascular events than placebo. Full VESALIUS-CV trial results: nej.md/4oWrIN6

#AHA25
November 8, 2025 at 3:36 PM
💬 Editorial: The GoFresh trial showed home-delivered DASH groceries modestly lowered BP and LDL cholesterol in Black adults, but high costs and diet design limit broader impact.

#AHA25 @ahascience.bsky.social

ja.ma/4hLvh6i
November 9, 2025 at 10:30 PM
ADAPT AF-DES trial: In patients with atrial fibrillation and a drug-eluting stent placed at least 1 year earlier, monotherapy with a non–vitamin K antagonist oral anticoagulant was noninferior to combination therapy with clopidogrel for net adverse clinical events. nej.md/4nH8DgK

#AHA25
November 8, 2025 at 7:35 PM
💾 Save this thread! Check out these key findings from today's JAMA, @jamacardiology.com, @jamainternalmed.com, and
@jamanetworkopen.com presentations at #AHA25. 🧵

Adding coronary CT angiography to traditional risk scores modestly improved prediction of first coronary events. ja.ma/4oyzvko
November 9, 2025 at 11:20 PM